Send to

Choose Destination
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:54-63. doi: 10.1016/j.pnpbp.2013.04.009. Epub 2013 Apr 19.

Monoamine neurocircuitry in depression and strategies for new treatments.

Author information

INSERM U894, Centre of Psychiatry and Neurosciences, Paris, France.


Extensive studies showed that monoaminergic neurotransmission that involves serotonin (5-HT), norepinephrine (NE) and dopamine (DA) exerts major influence on brain circuits concerned by the regulation of mood, reactivity to psychological stress, self-control, motivation, drive, and cognitive performance. Antidepressants targeting monoamines directly affect the functional tone of these circuits, notably in limbic and frontocortical areas, and evidence has been provided that this action plays a key role in their therapeutic efficacy. Indeed, at least some of functional changes detected by functional magnetic resonance imaging in emotion- and cognitive-related circuits such as the one involving limbic-cortical-striatal-pallidal-thalamic connections in depressed patients can be reversed by monoamine-targeted antidepressants. However, antidepressants acting selectively on only one monoamine, such as selective inhibitors of 5-HT or NE reuptake, alleviate depression symptoms in a limited percentage of patients, and are poorly effective to prevent recurrence. Thorough investigations for the last 30 years allowed the demonstration of the existence of functional interactions between 5-HT, NE and DA systems, and the identification of the specific receptors involved. In particular, 5-HT systems were shown to exert negative influence on NE and DA systems through 5-HT2A and 5-HT2C receptor- mediated mechanisms, respectively. On the other hand, complex positive and negative influences of NE system on 5-HT neurotransmission are mediated through α1- and α2-adrenergic receptors, respectively. These data provided a rationale for the design of new, multimodal, therapeutic strategies involving drugs acting not only at the "historical" targets such as the 5-HT and/or the NE transporter, but also at other molecular targets to improve their efficacy and their tolerability.


5-HT; 5-hydroxytryptamine, serotonin; BDNF; CA; CNS; CO-MED; CRH; Cg25; Combining Medications to Enhance Depression Outcomes; DA; DAT; DRN; HAM-D; HPA; Hamilton Depression rating scale; LCSPT; MADRS; MAOIs; MDD; MRI; Major depressive disorder; Monoamine neurocircuitry; Montgomery-Åsberg Depression Rating Scale; Multimodal antidepressants; N-methyl-D-aspartate; NE; NET; NMDA; NRIs; OFC; PET; PRL; QIDS-SR; Quick Inventory of Depressive Symptomatology: Self Rated; ROI; ReHo; SERT; SNP; SNRIs; SR; SSRIs; Serotonin receptors; TCAs; Tph2; VTA; brain derived neurotrophic factor; catecholamines; central nervous system; corticotropin-releasing hormone; dopamine; dopamine transporter; dorsal raphe nucleus; fMRI; functional magnetic resonance imaging; hypothalamo-pituitary-adrenal (axis); limbic-cortical-striatal-pallidal-thalamic (circuits); magnetic resonance imaging; major depressive disorder; mixed serotonin and norepinephrine reuptake inhibitors; monoamine oxidase inhibitors; norepinephrine; norepinephrine transporter; orbitofrontal cortex; positron emission tomography; prolactin; regional homogeneity; regions of interest; selective norepinephrine reuptake inhibitors; selective serotonin reuptake inhibitors; serotonin transporter; single nucleotide polymorphism; subgenual cingulate (Brodmann area 25); sustained release; tricyclic antidepressants; tryptophan hydroxylase-2; ventral tegmentum area

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center